--- title: 'SEC Reporting & Technical Accounting Consultant at Entrada Therapeutics' canonical: 'https://feeny.ai/job/sec-reporting-technical-accounting-consultant-entrada-therapeutics-boston-tbhf4v28p0a8' type: 'job' last_seen: '2026-10-18' --- # SEC Reporting & Technical Accounting Consultant at Entrada Therapeutics - **Company:** Entrada Therapeutics - **Location:** Boston, MA - **Posted:** 2026-09-24 - **Last confirmed live:** 2026-10-18 - **Apply:** https://job-boards.greenhouse.io/entradatherapeutics/jobs/5248567007 ## Job description The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670). We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families. The Opportunity Entrada Therapeutics is engaging a consultant to provide interim, full-time support to the SEC Reporting & Technical Accounting function from approximately mid-November 2026 through early March 2027. This engagement backfills priority pre-year-end and year-end deliverables while the Associate Director, SEC Reporting temporarily takes on additional responsibilities elsewhere in the accounting organization. The Associate Director will remain involved throughout the engagement and provide oversight/guidance as necessary. ## Responsibilities External Reporting: - Lead the preparation of the Company’s Form 10-K - Work closely with Controller, Associate Director SEC Reporting, COO and Legal to ensure all areas of our filings are complete and accurate - Assist with the preparation of earnings releases and Form 8-Ks, as needed - Prepare and/or review supporting schedules related to our external reporting - Coordinate and manage annual audit by external auditors and relationships with supporting consultants - Manage reporting timelines and communicate this clearly to relevant internal and external stakeholders - Assist with Audit Committee agenda oversight and preparation of meeting materials - Support preparation of the proxy statement as time allows Technical Accounting: - Manage the review of the Company annual tax provision and disclosures prepared by our external consultants - Support technical accounting research as needed and document conclusions reached in a clear, logical, and comprehensive manner - Collaborate with consultants for highly complex and judgmental technical accounting areas to ensure appropriate conclusions are reached - Provide support to accounting team and monthly close processes related to key accounting topics and areas of judgment. Additionally, assist in preparing and/or reviewing certain accounting close areas as needed (e.g., revenue, leases, investments, etc.) - Monitor development of emerging accounting pronouncements, determine the applicability to Entrada and support the implementation of new guidance, and communicate that to key stakeholders - Manage the development/improvement and implementation of accounting policies and procedures for all our processes to ensure consistency in reporting Controls and Compliance: - Lead year-end SOX 404(a) compliance to support 10-K SOX conclusions - Review SOC 1 reports for key vendors/service organizations - Work with third party consultant to finalize SOX testing work - Support Disclosure Committee agenda and related materials - Determine financial statement materiality and related posting thresholds - Other ad hoc projects with the Corporate Controller as needed The Necessities At Entrada, our passion for science, our devotion to patients and our values drives our behavior: - Humanity - We genuinely care about patients and about one another. - Tenacity - We are relentless and persistent in the pursuit of developing therapies for patients. - Creativity - We are creative problem solvers. - Collaboration - We are more than the sum of our parts. - Curiosity - We have a growth mindset and push conventional thought and theory. To thrive on our team, you will need to come with: - BA/BS degree with 7+ years of relevant experience or equivalent - Prior experience with a top accounting firm and experience gained in a Life Science environment is preferred - Experience working within a public company reporting structure is required - Strong proficiency with Microsoft Office related products - Experience with public company reporting required - Strong technical accounting experience and research capabilities to properly determine accounting conclusions on key technical matters. Experience with collaboration revenue recognition (ASC606) is strongly preferred - Knowledge of Accounting for Income Taxes (ASC 740) is strongly preferred - Extensive knowledge of SOX 404(a) controls and requirements - Experience with Workiva is a plus - A can-do attitude and appetite for learning new things, including support for research on new accounting pronouncements - You should be a strong communicator and have excellent organization skills - We are a high growth, Company; you must possess strong change agility skills and an ability to continue to perform at a high level through change #LI-Remote #LI-GG1 ## Equal Opportunity Employer Entrada Therapeutics is an equal opportunity employer. Qualified candidates will receive consideration for employment without regard to race, color, religion, national origin, gender, sexual orientation, gender identity or expression, age, mental or physical disability, and genetic information, marital status, citizenship status, military status, protected veteran status or any other category protected by law. Third Party Staffing Agencies Entrada does not accept unsolicited resumes from any source other than directly from candidates. For the protection of all parties involved in the recruiting process, resumes will only be accepted from recruiters/agencies if a signed agreement is in place at the inception of the recruiting effort and authorized for a specified position. Unsolicited resumes sent to Entrada from recruiters/agencies do not constitute any type of relationship between the recruiter/agency and Entrada and do not obligate Entrada to pay fees if we hire from those resumes. Privacy Statement Entrada Therapeutics, Inc. (the “Entrada,” “we,” “us,” or “our”) respects your privacy and we want you to be familiar with how we collect, use, share, or otherwise process, your Personal Information. Please reference our privacy statement [here](https://www.entradatx.com/privacy-notice)to understand how and when your data is being used. ## About Entrada Therapeutics ## Company Overview - **One-liner**: Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary Endosomal Escape Vehicle (EEV™) platform to deliver genetic medicines to previously inaccessible intracellular targets for devastating diseases. - **Entity Type**: Public (NASDAQ: TRDA) - **Headquarters**: Boston, Massachusetts, United States - **Founded**: 2016 - **Founders**: Not publicly listed on the company website; leadership team includes CEO Dipal Doshi, CFO Kory Wentworth, and President of R&D Natarajan Sethuraman. ## Core Business - **Primary industry**: Biotechnology – genetic medicines and intracellular therapeutics - **Target customers**: B2B (partnerships with pharma like Vertex) and ultimately patients with rare neuromuscular and retinal diseases - **Mission**: To treat devastating diseases with intracellular therapeutics, focusing on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and inherited retinal diseases. ## Products & Services - **EEV™ Platform**: A proprietary, modular delivery technology designed to enable efficient intracellular delivery of oligonucleotides, proteins, and other therapeutics into a wide range of tissues (muscle, retina, etc.) with an improved therapeutic index. - **Clinical-stage programs (DMD franchise)**: - ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51 – exon-skipping oligonucleotides for DMD patients amenable to skipping exons 44, 45, 50, and 51. Multiple programs have advanced into clinical trials in the U.K., EU, and U.S. - **Collaboration program**: - VX-670 (with Vertex Pharmaceuticals) – a clinical-stage therapy for myotonic dystrophy type 1 (DM1). - **Pipeline (preclinical)**: Additional programs in neuromuscular and inherited retinal diseases. ## Market Standing - **Valuation/Market Cap**: $711.3 million (as of mid-2026, per LinkedIn data) - **Key Metric (Revenue)**: $25.4 million annual revenue (2025/2026 estimate from LinkedIn) - **Notable Investors/Partners**: Vertex Pharmaceuticals (strategic collaboration); publicly traded with institutional investors - **Growth Signals**: - IPO in 2021 - 2026 described as a “catalyst-rich period” with multiple clinical data readouts expected - Four clinical-stage DMD programs by year-end 2026 - Positive safety data from ELEVATE-45-201 study leading to dose escalation (10 mg/kg cohort) - Headcount of 168 employees (down ~6% YoY, indicating possible restructuring or natural attrition) ## Competitive Advantages - **Proprietary EEV™ Platform**: Enables intracellular delivery of large molecules that cannot cross cell membranes, unlocking “undruggable” targets – a significant differentiator in the genetic medicine space. - **Modular and versatile**: Platform can be applied across multiple therapeutic areas (neuromuscular, retinal, metabolic) and modalities (oligonucleotides, proteins, gene editors). - **Deep DMD franchise**: Entrada is building one of the broadest exon-skipping pipelines for DMD, targeting multiple patient subpopulations. - **Strategic partnership with Vertex**: Validates the platform and provides co-development resources for DM1. ## Strategic Focus - **Near-term**: Deliver clinical proof-of-concept for DMD programs (data readouts through 2026) and advance VX-670 in DM1. - **Pipeline expansion**: Continue to broaden the EEV platform into new tissues and disease areas, including inherited retinal diseases and metabolic disorders. - **Commercial readiness**: Build internal capabilities for potential future product launches while maintaining a lean, high-impact R&D organization. ## Why Work Here - **Culture**: Described as a “tight-knit team of experts and leaders” with a mission-driven, collaborative, and high-energy environment. Values include humanity, curiosity, and a growth mindset. - **Diversity & Inclusion**: As of October 2025, 58% of employees identify as women, 45% as Asian, Hispanic, Latino, African American, or two or more races; 64% of senior leadership and board are women and minorities. Employee Resource Groups (ERGs) are active. - **Work Model**: Flexible working – role-dependent remote options; employees choose where they work best. Commuter benefits (up to $325/month) for those who come to the Boston Seaport office. - **Benefits**: Comprehensive – fully subsidized lunches/snacks, $500 wellbeing stipend, gender-inclusive parental leave, education reimbursement, mental health and financial coaching, HSA contributions, and milestone celebrations. - **Perks**: In-office fuel (free food/drinks), regular team events, and a strong emphasis on work-life balance. - **Open Roles**: Positions include clinical trial management, regulatory affairs, drug substance development, IT support, and more – posted on Greenhouse. ## Sources 1. [entradatx.com](https://www.entradatx.com/) – Company overview, platform, pipeline, mission 2. [entradatx.com/about](https://www.entradatx.com/about) – Leadership team, company history 3. [entradatx.com/careers](https://www.entradatx.com/careers) – Culture, benefits, diversity stats, open positions 4. [linkedin.com/company/entradatx](https://www.linkedin.com/company/entradatx) – Headcount, revenue, market cap, industry classification 5. [job-boards.greenhouse.io/entradatherapeutics](http://job-boards.greenhouse.io/entradatherapeutics) – Current job listings ## Other roles at Entrada Therapeutics - [Manager, Commercial Strategy Analytics](https://feeny.ai/job/manager-commercial-strategy-analytics-entrada-therapeutics-boston-93h032mf0742) — Boston, MA - [Clinical Scientist (CONSULTANT)](https://feeny.ai/job/clinical-scientist-consultant-entrada-therapeutics-boston-sn71hza1h4vt) — Boston, MA - [Senior Clinical Operations Contractor](https://feeny.ai/job/senior-clinical-operations-contractor-entrada-therapeutics-boston-ywx802nhvaen) — Boston, MA - [Associate Director, Drug Product Development & Manufacturing](https://feeny.ai/job/associate-director-drug-product-development-manufacturing-entrada-therapeutics-p593cry5gk61) — Boston, MA - [Associate Director, Analytical Development & Quality Control](https://feeny.ai/job/associate-director-analytical-development-quality-control-entrada-therapeutics-z1f7fbqpchmp) — Boston, MA - [Director, Regulatory Writing](https://feeny.ai/job/director-regulatory-writing-entrada-therapeutics-boston-ab86t5fmrhhn) — Boston, MA